文献速递其他结缔组织病

FDG-PET/CT可区分原发性干燥综合征患者是否合并淋巴瘤

FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究纳入70例ACR-EULAR阳性原发性干燥综合征患者,评估FDG-PET/CT区分是否合并淋巴瘤及评估系统性疾病活动度的价值。淋巴瘤患者腮腺和颌下腺FDG摄取更高、结节性肺部病变更常见;联合三项特征后灵敏度92%、特异度91%。FDG-PET/CT可辅助排除无PET异常患者的淋巴瘤,并指导活检部位。

要点

  • 淋巴瘤患者腮腺和颌下腺FDG摄取高于非淋巴瘤患者
  • 腮腺SUVmax>3.1和颌下腺SUVmax>2.9为预测淋巴瘤的最佳界值
  • 联合结节性肺部病变等三项特征,至少一项阳性灵敏度92%,至少两项阳性特异度91%

核心结论

  • FDG-PET/CT可辅助排除无PET异常的原发性干燥综合征相关淋巴瘤,可能减少疑似淋巴瘤患者的侵入性活检。
  • FDG-PET/CT能检测原发性干燥综合征的系统性表现,并可指导最佳活检部位。

研究设计与样本

  • 纳入ACR-EULAR阳性且接受FDG-PET/CT检查的原发性干燥综合征患者,共70例。
  • 对扫描进行视觉评估,并定量测量唾液腺、泪腺及全身区域的标准化摄取值(SUV)。
  • 采用受试者工作特征曲线分析寻找区分淋巴瘤与非淋巴瘤的SUV界值。

主要发现

  • 70例患者中26例诊断为原发性干燥综合征相关淋巴瘤,其中23/26为黏膜相关淋巴组织型。
  • 淋巴瘤患者腮腺和颌下腺FDG摄取高于非淋巴瘤患者,且结节性肺部病变更常见。
  • 腮腺SUVmax和颌下腺SUVmax预测淋巴瘤诊断的准确度良好,最佳界值分别为3.1和2.9。
  • 联合结节性肺部病变、腮腺SUVmax>3.1和颌下腺SUVmax>2.9三项特征,至少一项阳性时灵敏度92%,至少两项阳性时特异度91%。
  • FDG-PET/CT可检测原发性干燥综合征的系统性表现,主要累及淋巴结、附着点和肺部。

关键数值与推荐

  • 腮腺SUVmax最佳界值为3.1,颌下腺SUVmax最佳界值为2.9。
  • 联合三项特征至少一项阳性时灵敏度92%,至少两项阳性时特异度91%。

临床怎么用

  • FDG-PET/CT可辅助排除无PET异常患者的原发性干燥综合征相关淋巴瘤,可能减少疑似淋巴瘤患者的侵入性活检。
  • FDG-PET/CT可检测原发性干燥综合征的系统性表现,并可指导最佳活检部位。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the usefulness of [18F]-fluorodeoxyglucose (FDG)-PET/CT (i) to discriminate between primary SS (pSS) patients with and without lymphomas and (ii) to evaluate systemic disease activity in pSS. METHODS: ACR-EULAR-positive pSS patients who underwent FDG-PET/CT were included. Scans were visually evaluated and quantitative analysis was performed by measuring standardized uptake values (SUV) of salivary and lacrimal glands and systemic regions. Receiver operating characteristic curve analyses were performed to find SUV cut-off values to discriminate between lymphoma and non-lymphoma. RESULTS: Of the 70 included patients, 26 were diagnosed with a pSS-associated lymphoma, mostly of the mucosa-associated lymphoid tissue type (23/26). Lymphoma patients showed higher FDG uptake in the parotid and submandibular glands, and more frequently showed presence of nodular lung lesions, compared with non-lymphoma patients. The accuracy of the maximum SUV (SUVmax) in the parotid and submandibular gland to predict lymphoma diagnosis was good, with optimal cut-off points of 3.1 and 2.9. After combining these three visual and quantitative findings (nodular lung lesions, parotid SUVmax > 3.1 and submandibular SUVmax > 2.9), sensitivity was 92% when at least one of the three features were present, and specificity was 91% in case at least two features were present. Furthermore, FDG-PET/CT was able to detect systemic manifestations in pSS patients, mostly involving lymph nodes, entheses and lungs. CONCLUSIONS: FDG-PET/CT can assist in excluding pSS-associated lymphomas in patients without PET abnormalities, possibly leading to a decrease of invasive biopsies in suspected lymphoma patients. Furthermore, FDG-PET/CT is able to detect systemic manifestations in pSS and can guide to the best biopsy location.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van Ginkel MS, Arends S, van der Vegt B, et al. FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren's syndrome. Rheumatology (Oxford). 2023. PMID: 36759907. doi:10.1093/rheumatology/kead071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。